Nathan Cantoni
Real-world Data From the Swiss Lenalidomide in MDS del(5q) (SLIM)-Registry Identify New Chances and Challenges in Lenalidomide Treatment of Patients With MDS del(5q).
Rüfer A, Angermann H, Benz R, Bonadies N, Calderoni A, Cantoni N, Efthymiou A, Escher R, Favre G, Friess D, Gschwend A, Himmelmann A, Holbro A, Keller P, Kouroupi E, Lehmann T, Pedarnig N, Rigamonti V, Samii K, Schmidt A, Schäfer H, Sperb R, Stussi G, Winkler A, Zenhäusern R, Goede J. Real-world Data From the Swiss Lenalidomide in MDS del(5q) (SLIM)-Registry Identify New Chances and Challenges in Lenalidomide Treatment of Patients With MDS del(5q). Hemasphere 2022; 6:e741.
Jun 17, 2022Real-world Data From the Swiss Lenalidomide in MDS del(5q) (SLIM)-Registry Identify New Chances and Challenges in Lenalidomide Treatment of Patients With MDS del(5q).
Jun 17, 2022Hemasphere 2022; 6:e741
Rüfer Axel, Angermann Hubert, Benz Rudolf, Bonadies Nicolas, Calderoni Antonello, Cantoni Nathan, Efthymiou Anna, Escher Robert, Favre Geneviève, Friess Dorothea, Gschwend Andreas, Himmelmann Andreas, Holbro Andreas, Keller Peter, Kouroupi Eirini, Lehmann Thomas, Pedarnig Nikolaus, Rigamonti Véronique, Samii Kaveh, Schmidt Adrian, Schäfer Hans-Peter, Sperb Roland, Stussi Georg, Winkler Annette, Zenhäusern Reinhard, Goede Jeroen
Outcome and Prognostic Factors of COVID-19 Infection in Swiss Cancer Patients: Final Results of SAKK 80/20 (CaSA).
Jörger M, Metaxas Y, Zaman K, Michielin O, Mach N, Bettini A, Schmitt A, Cantoni N, Caspar C, Stettler S, Malval R, Pless M, Britschgi C, Renner C, Koeberle D, Schulz J, Kopp C, Hayoz S, Stathis A, von Moos R, Swiss Group for Clinical Cancer Research (SAKK). Outcome and Prognostic Factors of COVID-19 Infection in Swiss Cancer Patients: Final Results of SAKK 80/20 (CaSA). Cancers (Basel) 2022; 14
Apr 27, 2022Outcome and Prognostic Factors of COVID-19 Infection in Swiss Cancer Patients: Final Results of SAKK 80/20 (CaSA).
Apr 27, 2022Cancers (Basel) 2022; 14
Jörger Markus, Metaxas Yannis, Zaman Khalil, Michielin Olivier, Mach Nicolas, Bettini Adrienne, Schmitt Andreas M, Cantoni Nathan, Caspar Clemens B, Stettler Sonja, Malval Roma, Pless Miklos, Britschgi Christian, Renner Christoph, Koeberle Dieter, Schulz Jessica D, Kopp Christoph, Hayoz Stefanie, Stathis Anastasios, von Moos Roger, Swiss Group for Clinical Cancer Research (SAKK)
Prospective long-term follow-up after first-line subcutaneous cladribine in hairy cell leukemia: a SAKK trial
Benz R, O'Meara Stern A, Cantoni N, Bargetzi M, Bianchi-Papina E, Rossi D, Passweg J, Lohri A, Berardi S, Feller A, Rauch D, Blum S, Mey U, Arn K, Andres M, Pabst T, Baumann M, Novak U, Hitz F, Hess U, Zenhaeusern R, Chalandon Y, Stussi G. Prospective long-term follow-up after first-line subcutaneous cladribine in hairy cell leukemia: a SAKK trial. Blood Adv 2020; 4:3699-3707.
Aug 11, 2020Prospective long-term follow-up after first-line subcutaneous cladribine in hairy cell leukemia: a SAKK trial
Aug 11, 2020Blood Adv 2020; 4:3699-3707
Benz Rudolf, O'Meara Stern Alix, Cantoni Nathan, Bargetzi Mario, Bianchi-Papina Elena, Rossi Davide, Passweg Jakob, Lohri Andreas, Berardi Simona, Feller Anita, Rauch Daniel, Blum Sabine, Mey Ulrich, Arn Kornelius, Andres Martin, Pabst Thomas, Baumann Michael, Novak Urban, Hitz Felicitas, Hess Urs, Zenhaeusern Reinhard, Chalandon Yves, Stussi Georg
SDHA gain-of-function engages inflammatory mitochondrial retrograde signaling via KEAP1-Nrf2
Burgener A, Dimeloe S, Lötscher J, Sauder U, Ebnöther M, Burger B, Heijnen I, Martínez-Cano S, Cantoni N, Brücker R, Kahlert C, Sancho D, Jones R, Navarini A, Recher M, Epple R, Grählert J, Müller-Durovic B, Bantug G, Meyer B, Higgins R, Ghosh A, Bignucolo O, Ma E, Loeliger J, Unterstab G, Geigges M, Steiner R, Enamorado M, Ivanek R, Hunziker D, Schmidt A, Hess C. SDHA gain-of-function engages inflammatory mitochondrial retrograde signaling via KEAP1-Nrf2. Nat Immunol 2019; 20:1311-1321.
Sep 16, 2019SDHA gain-of-function engages inflammatory mitochondrial retrograde signaling via KEAP1-Nrf2
Sep 16, 2019Nat Immunol 2019; 20:1311-1321
Burgener Anne-Valérie, Dimeloe Sarah, Lötscher Jonas, Sauder Ursula, Ebnöther Monika, Burger Bettina, Heijnen Ingmar, Martínez-Cano Sarai, Cantoni Nathan, Brücker Rolf, Kahlert Christian, Sancho David, Jones Russell G, Navarini Alexander, Recher Mike, Epple Raja, Grählert Jasmin, Müller-Durovic Bojana, Bantug Glenn R, Meyer Benedikt J, Higgins Rebecca, Ghosh Adhideb, Bignucolo Olivier, Ma Eric H, Loeliger Jordan, Unterstab Gunhild, Geigges Marco, Steiner Rebekah, Enamorado Michel, Ivanek Robert, Hunziker Danielle, Schmidt Alexander, Hess Christoph
Promising activity of nelfinavir-bortezomib-dexamethasone (NeVd) in proteasome inhibitor-refractory multiple myeloma
Driessen C, Pabst T, Hitz F, Hawle H, Rondeau S, Berset C, Besse A, Besse L, Ribi K, Samaras P, Mey U, Rüfer A, Mach N, Betticher D, Cantoni N, Novak U, Müller R, Zander T. Promising activity of nelfinavir-bortezomib-dexamethasone (NeVd) in proteasome inhibitor-refractory multiple myeloma. Blood 2018
Sep 20, 2018Promising activity of nelfinavir-bortezomib-dexamethasone (NeVd) in proteasome inhibitor-refractory multiple myeloma
Sep 20, 2018Blood 2018
Driessen Christoph, Pabst Thomas, Hitz Felicitas, Hawle Hanne, Rondeau Stephanie, Berset Catherine, Besse Andrej, Besse Lenka, Ribi Karin, Samaras Panagiotis, Mey Ulrich, Rüfer Axel, Mach Nicolas, Betticher Daniel, Cantoni Nathan, Novak Urban, Müller Rouven, Zander Thilo
Trends of classification, incidence, mortality, and survival of MDS patients in Switzerland between 2001 and 2012.
Bonadies N, Feller A, Rovó A, Ruefer A, Blum S, Gerber B, Stuessi G, Benz R, Cantoni N, Holbro A, Schmidt A, Lehmann T, Wilk C, Arndt V, NICER Working Group. Trends of classification, incidence, mortality, and survival of MDS patients in Switzerland between 2001 and 2012. Cancer Epidemiol 2017; 46:85-92.
Jan 2, 2017Trends of classification, incidence, mortality, and survival of MDS patients in Switzerland between 2001 and 2012.
Jan 2, 2017Cancer Epidemiol 2017; 46:85-92
Bonadies Nicolas, Feller Anita, Rovó Alicia, Ruefer Axel, Blum Sabine, Gerber Bernhard, Stuessi Georg, Benz Rudolf, Cantoni Nathan, Holbro Andreas, Schmidt Adrian, Lehmann Thomas, Wilk C Matthias, Arndt Volker, NICER Working Group
Bendamustine, lenalidomide and dexamethasone (BRd) has high activity as 2(nd) -line therapy for relapsed and refractory multiple myeloma - a phase II trial
Mey U, Ruefer A, Ziske C, Knauf W, Cathomas R, von Moos R, Hitz F, Sauter R, Hiendlmeyer E, Cantoni N, Bargetzi M, Fischer N, Doerfel S, Brugger W, Schwarb H, Pederiva S, Schwarzer A, Dechow T, Jehner P, Rauh J, Taverna C, Schmid M, Schmidt-Hieber M, Driessen C. Bendamustine, lenalidomide and dexamethasone (BRd) has high activity as 2(nd) -line therapy for relapsed and refractory multiple myeloma - a phase II trial. Br J Haematol 2016
Dec 16, 2016Bendamustine, lenalidomide and dexamethasone (BRd) has high activity as 2(nd) -line therapy for relapsed and refractory multiple myeloma - a phase II trial
Dec 16, 2016Br J Haematol 2016
Mey Ulrich J M, Ruefer Axel, Ziske Carsten, Knauf Wolfgang, Cathomas Richard, von Moos Roger, Hitz Felicitas, Sauter Rafael, Hiendlmeyer Elke, Cantoni Nathan, Bargetzi Mario, Fischer Natalie, Doerfel Steffen, Brugger Wolfram, Schwarb Heike, Pederiva Stefanie, Schwarzer Andreas, Dechow Tobias, Jehner Paul, Rauh Jacqueline, Taverna Christian J, Schmid Mathias, Schmidt-Hieber Martin, Driessen Christoph